Literature DB >> 7874570

Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma.

D V Habif1, L Ozzello, C M De Rosa, K Cantell, R Lattes.   

Abstract

Two groups of patients with disseminated breast carcinomas who had failed radiotherapy, chemotherapy, and hormonotherapy were treated with natural interferon alpha (nIFN-alpha) alone or in combination with nIFN-gamma delivered in cycles of 10-12 intralesional (i.l.) injections to recurrent and metastatic lesions. In group, I, 16 skin lesions in 12 patients received nIFN-alpha alone resulting in 7 complete regressions verified histologically (CR), 7 partial regressions (PR), and no regressions (NR) in 2. Group II included 4 patients in whom 7 cutaneous recurrences were treated with nIFN-alpha/nIFN-gamma (5 CR, 2 PR), 2 were injected with nIFN-alpha alone (1 CR, 1 PR), and 1 received nIFN-gamma alone (PR). Two additional patients in group II were given i.l. injections of nIFN-alpha/nIFN-gamma to lymph node metastases (1 CR, 1 PR). Clinical toxicity was experienced by 5 of 12 patients in group I and by all the patients in group II and was controlled in most instances by antipyretics. Systemic antitumor effects were not appreciable clinically. Nevertheless, noninjected lesions exposed only to systemic levels of IFNs, when studied immunohistochemically, displayed an immunological response similar to that of IFN-injected lesions, although less intense. Therefore, IFNs can be useful in controlling locoregional recurrences of breast cancer even in patients who are not responding to other forms of therapy. Furthermore, in addition to the local antitumor actions, they appear to be capable of eliciting systemic immunological effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7874570     DOI: 10.3109/07357909509011686

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  6 in total

1.  Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review.

Authors:  Ashley Drohan; Dejan Vidovic; Penelope Jane Barnes; Carman Anthony Giacomantonio; Lucy Kathryn Helyer
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

2.  Response of cutaneous metastases from breast cancer to capecitabine.

Authors:  Kostandinos Sideras; Katie M Zahasky; Judith S Kaur
Journal:  Clin Med Oncol       Date:  2008-04-18

Review 3.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.

Authors:  Flávia Castro; Ana Patrícia Cardoso; Raquel Madeira Gonçalves; Karine Serre; Maria José Oliveira
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

Review 4.  Cutaneous metastasectomy: Is there a role in breast cancer? A systematic review and overview of current treatment modalities.

Authors:  Samantha Huang; Vishwas Parekh; James Waisman; Veronica Jones; Yuan Yuan; Nayana Vora; Richard Li; Jae Jung; Laura Kruper; Farah Abdulla; Yuman Fong; Wai-Yee Li
Journal:  J Surg Oncol       Date:  2022-04-07       Impact factor: 2.885

5.  Influence of IFN-gamma and its receptors in human breast cancer.

Authors:  Ignacio García-Tuñón; Mónica Ricote; Antonio Ruiz A; Benito Fraile; Ricardo Paniagua; Mar Royuela
Journal:  BMC Cancer       Date:  2007-08-14       Impact factor: 4.430

6.  Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity.

Authors:  Marie-Claude Bourgeois-Daigneault; Dominic Guy Roy; Theresa Falls; Kwame Twumasi-Boateng; Lauren Elizabeth St-Germain; Monique Marguerie; Vanessa Garcia; Mohammed Selman; Victoria Ann Jennings; Jessica Pettigrew; Sally Amos; Jean-Simon Diallo; Brad Nelson; John Cameron Bell
Journal:  Mol Ther Oncolytics       Date:  2016-02-17       Impact factor: 7.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.